Spendlove I - Search Results

1

A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

Ullenhag GJ, Spendlove I, Watson NF, Indar AA, Dube M, Robins RA, Maxwell-Armstrong C, Scholefield JH, Durrant LG. Ullenhag GJ, et al. Among authors: spendlove i. Clin Cancer Res. 2006 Dec 15;12(24):7389-96. doi: 10.1158/1078-0432.CCR-06-1003. Epub 2006 Nov 22. Clin Cancer Res. 2006. PMID: 17121873 Clinical Trial.

2

Cancer vaccines.

Durrant LG, Spendlove I. Durrant LG, et al. Among authors: spendlove i. QJM. 1996 Sep;89(9):645-51. doi: 10.1093/qjmed/89.9.645. QJM. 1996. PMID: 8917739 Review. No abstract available.

3

Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity.

Durrant LG, Buckley DJ, Spendlove I, Robins RA. Durrant LG, et al. Among authors: spendlove i. Hybridoma. 1997 Feb;16(1):23-6. doi: 10.1089/hyb.1997.16.23. Hybridoma. 1997. PMID: 9085124 Clinical Trial.

4

Decay accelerating factor (CD55): a target for cancer vaccines?

Spendlove I, Li L, Carmichael J, Durrant LG. Spendlove I, et al. Cancer Res. 1999 May 15;59(10):2282-6. Cancer Res. 1999. PMID: 10344729

5

105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.

Durrant LG, Buckley DJ, Robins RA, Spendlove I. Durrant LG, et al. Among authors: spendlove i. Int J Cancer. 2000 Jan 1;85(1):87-92. doi: 10.1002/(sici)1097-0215(20000101)85:1<87::aid-ijc16>3.0.co;2-k. Int J Cancer. 2000. PMID: 10585589 Clinical Trial.

6

CD55 is over-expressed in the tumour environment.

Li L, Spendlove I, Morgan J, Durrant LG. Li L, et al. Among authors: spendlove i. Br J Cancer. 2001 Jan 5;84(1):80-6. doi: 10.1054/bjoc.2000.1570. Br J Cancer. 2001. PMID: 11139317 Free PMC article.

7

Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses.

Durrant LG, Parsons T, Moss R, Spendlove I, Carter G, Carr F. Durrant LG, et al. Among authors: spendlove i. Int J Cancer. 2001 May 1;92(3):414-20. doi: 10.1002/ijc.1194. Int J Cancer. 2001. PMID: 11291080

8

Immunization against tumor cell surface complement-regulatory proteins.

Durrant LG, Spendlove I. Durrant LG, et al. Among authors: spendlove i. Curr Opin Investig Drugs. 2001 Jul;2(7):959-66. Curr Opin Investig Drugs. 2001. PMID: 11757799 Review.

9

The role of CD55 in protecting the tumour environment from complement attack.

Morgan J, Spendlove I, Durrant LG. Morgan J, et al. Among authors: spendlove i. Tissue Antigens. 2002 Sep;60(3):213-23. doi: 10.1034/j.1399-0039.2002.600303.x. Tissue Antigens. 2002. PMID: 12445304

10

International conference: progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK.

Rees RC, Robins RA, Pawelec G, Muller L, Li G, Spendlove I. Rees RC, et al. Among authors: spendlove i. Cancer Immunol Immunother. 2003 Jun;52(6):403-7. doi: 10.1007/s00262-002-0366-3. Epub 2003 Apr 9. Cancer Immunol Immunother. 2003. PMID: 12684847 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters